Insulin Family intermediate
Peakless Basal Insulin Profiles
Pharmacokinetic concept of flat, peakless basal insulin action profiles achieved by ultra-long-acting insulin analogues.
By Encyclopeptide Editorial | 1 min read
insulin basal pharmacokinetics flat-profile hypoglycemia
Overview
Peakless basal insulin aims to mimic continuous, low-level pancreatic insulin secretion. Traditional NPH insulin has a pronounced peak-and-trough profile, while modern analogues achieve flatter pharmacokinetics.
Comparative Profiles
| Insulin | Peak-Trough Ratio | Duration | Hypoglycemia Risk |
|---|---|---|---|
| NPH | 3-4x | 12-18h | Higher |
| Glargine U100 | 1.5-2x | ~24h | Moderate |
| Degludec | ~1.2x | >42h | Lowest |
| Glargine U300 | ~1.3x | >30h | Low |
Clinical Benefits
- Reduced nocturnal hypoglycemia
- More predictable glucose levels
- Flexible dosing time
- Less glucose variability
Chemical Identity
| Property | Value |
|---|---|
| Name | Peakless Basal Insulin Profiles |
| Category | Insulin Family |
References
- Encyclopeptide Database. “Peakless Basal Insulin Profiles” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Peakless Basal Insulin Profiles with interactive quizzes on Wikipept.
Take a Quiz on Wikipept